AI entity

University of Pittsburgh

organization

All 1 tracked stories fall under one category: ai-research. Of the tracked stories, 1 of 1 also mention GLP-1 Agonists, the most common co-covered peer. Each story carries 6 original sources on average, compared with 2.4 for the broader beat in this window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · University of Pittsburgh

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about University of Pittsburgh

All 1 tracked stories fall under one category: ai-research. Of the tracked stories, 1 of 1 also mention GLP-1 Agonists, the most common co-covered peer. Each story carries 6 original sources on average, compared with 2.4 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6.8 for that window. We currently track 1 AI story that mention University of Pittsburgh, all published on March 19, 2026.

Stories tracked
1
Sources per story
6

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 36 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering University of Pittsburgh. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning University of Pittsburgh 1

Research Positive

Pitt Researchers Leverage AI to Break Leptin Resistance in Obesity Treatment

Researchers at the University of Pittsburgh have unveiled a novel AI-driven approach to obesity drug development focused on restoring leptin sensitivity. This computational method identifies small molecules capable of bypassing leptin resistance, potentially offering a more targeted alternative to current GLP-1 therapies.

6 sources

University of Pittsburgh is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.